Tendering and value-based pricing: Lessons from Italy on human papilloma virus vaccines

Journal of the Royal Society of Medicine

Volumn 107, Issue 1, 2014, Pages 4-5

  Garattini, Livio ^a   Van de Vooren, Katelijne ^a   Freemantle, Nick ^b  

^a IRCCS Institute for Pharmacological Research Mario Negri   (Italy)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADULT; COST EFFECTIVENESS ANALYSIS; DRUG COST; EDITORIAL; FEMALE; HEALTH ECONOMICS; HOSPITAL PURCHASING; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; ITALY; MIDDLE AGED; NATIONAL HEALTH SERVICE; NONHUMAN; PAPILLOMAVIRUS INFECTION; UTERINE CERVIX CANCER; VACCINATION; WART VIRUS; YOUNG ADULT;

EID: 84891858881     PISSN: 01410768     EISSN: None     Source Type: Journal    
DOI: 10.1177/0141076813512122     Document Type: Editorial

References (10)

1. Garattini L,van de Vooren K,Curto A.Pricing human papillomavirus vaccines: lessons from Italy.Pharmacoeconomics. 2012;30:213-17.
2. Godlee F.Why don't we know how much vaccines cost?.BMJ. 2011;343:d6239-d6239.
3. Department of Health - Commercial Medicines Unit. Contract for the Supply of Human Papillomavirus Vaccine in UK, 2011. See http://www.contractsfinder.businesslink.gov.uk/Common/View%20Notice.aspx?site=1000&lang=en¬iceid=184264&fs=true (accessed 8 October 2013).
4. Klemperer P.Bidding markets.J Competition Law Econ. 2007;3:1-47.
5. Carone G, Schwierz C, Xavier A. Cost-containment Policies in Public Pharmaceutical Spending in the EU. European Commission. Economic Papers 461, September 2012.
6. Kim SY,Goldie SJ.Cost-effectiveness analyses of vaccination programmes. A focused review of modelling approaches.Pharmacoeconomics. 2008;26:191-215.
7. Koleva D,De Compadri P,Padula A,Garattini L.Economic evaluation of human papilloma virus vaccination in the European Union: a critical review.Intern Emerg Med. 2011;6:163-74.
8. Freemantle N,Maynard A.Something rotten in the state of clinical and economic analyses.Health Econ. 1994;3:63-7.
9. Claxton K,Briggs A,Buxton MJ, et al.Value based pricing for NHS drugs: an opportunity not to be missed?.BMJ. 2008;336:251-4.
10. Equity and Excellence: Liberating the NHS (White Paper). UK: Department of Health; 2010:.